FILING ANALYSIS · THURSDAY, NOVEMBER 12
SeaStar Medical Holding Corp ICU — 8-K: Results of Operations and Financial Condition
neutral
The company reported a 247% increase in net revenue compared to the third quarter of 2025, driven by the adoption of the QUELIMMUNE therapy, and achieved nearly 75% enrollment in the NEUTRALIZE-AKI pivotal clinical trial, but no specific guidance or quantified surprise was disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →